Results 91 to 100 of about 59,439 (317)

Advances in GPCRs Associated With Wnt Signaling Within the Auditory System

Medicine Bulletin, EarlyView.
ABSTRACT G protein‐coupled receptors (GPCRs) that interact with the Wnt signaling pathway are pivotal for auditory system homeostasis, as they orchestrate inner ear development, hair cell (HC) regeneration, and hearing preservation. Frizzled (FZD) receptors, the core Wnt‐related GPCRs, bind Wnt ligands and co‐receptors (e.g., LRP5/6) to activate both ...
Liang Wang, Changling Xu, Jiangang Fan, Renjie Chai   +3 more
wiley   +1 more source

NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development

Neuropsychopharmacology Reports
Background An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022.
Myfanwy Graham, Edward Eden, Kelsey Maddison, Luise Lago, Samuel Allingham, Catherine J. Lucas, Jennifer Schneider, Jennifer H. Martin   +7 more
doaj   +1 more source

Cannabinoids for the control of experimental multiple sclerosis

, 2010
PhDThere have been numerous studies reporting that cannabinoids, both exogenous and endogenous, have a potential beneficial function during incidences of neurological damage.
Pryce, Gareth
core  

Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease

, 2014
The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD).
Silvia Cianci, ROMANO, ADELE, Romano, A, M. r. Elphick, Gianluigi Vendemiale, Pace, Lorenzo, Elphick, Maurice R, Bedse, G, Angelo M. Lavecchia, Gaurav Bedse, GAETANI, SILVANA, VENDEMIALE, GIANLUIGI, LAVECCHIA, ANGELO MICHELE, @CORRESPONDING AUTHOR, Vendemiale, G, CIANCI, SILVIA, Pace Lorenzo, Lorenzo Federico Pace, Adele Romano, Gaetani, S, Tommaso Cassano, BEDSE, GAURAV, Lorenzo, P, Caterina Grillo, Cassano, T, Grillo, C, Laferla, Frank M, ALTIERI, Fabio, Elphick, MR, LaFerla, FM, Maurice R. Elphick, GRILLO, CATERINA, Silvana Gaetani, Frank M. LaFerla, F. m. Laferla, CASSANO, TOMMASO, Lavecchia, AM, Fabio Altieri, Altieri, F, Cianci, S   +39 more
core   +1 more source

Synthetic cannabinoids

Northern Clinics of Istanbul, 2014
Use of cannabinoids is increasing at an alarming rate. Their easy availability, cheapness, perceptive legality and difficulty in detecting its presence with standard urine toxicologic tests, and similar factors probably contribute to the increased use, and popularity of synthetic cannabinoids. Although laws, and regulations concerning auditing of these
openaire   +2 more sources

High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fibromyalgia is characterized by widespread pain, fatigue, sleep and cognitive symptoms. It overlaps clinically with functional motor disorder (FMD), yet its prevalence and impact in FMD remain uncertain. Objective To determine the prevalence of fibromyalgia in FMD using the current criteria and evaluate its effects on motor ...
Tereza Serranová, Lucia Nováková, Martin Jirásek, Barbora Křupková, Evžen Růžička, Michele Tinazzi, Tomáš Sieger   +6 more
wiley   +1 more source

CANNABINOIDS REGULATE TYPE 1 CANNABINOID RECEPTOR EXPRESSION IN CELL CULTURE MODELS OF HUNTINGTON'S DISEASE

, 2012
Type 1 cannabinoid receptor (CB1) levels decline in the striatum of animal models of Huntington’s disease (HD) and in the brains of human patients suffering from HD prior to other pathogenic changes.
Laprairie, Robert
core  

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Type 1 cannabinoid receptor-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons.

, 2009
Hypophysiotropic TRH-synthesizing neurons of the hypothalamic paraventricular nucleus (PVN) have a critical role in the regulation of the energy homeostasis through control of the hypothalamic-pituitary-thyroid axis.
Wittmann, Gábor, Fekete, Csaba, Liposits, Zsolt, Watanabe, Masahiko, Deli, Levente, Lechan, Ronald M., Kalló, Imre   +6 more
core